DTPA(DOTA)-Nimotuzumab Radiolabeling with Generator-Produced Thorium for Radioimmunotherapy of EGFR-Overexpressing Carcinomasстатья
Информация о цитировании статьи получена из
Scopus
Статья опубликована в журнале из списка Web of Science и/или Scopus
Дата последнего поиска статьи во внешних источниках: 17 июля 2024 г.
Аннотация:Thorium-226 is a promising radioisotope for radioimmunotherapy. Here, we have prepared two “in-house” 230Pa/230U/226Th tandem generators consisting of an anion exchanger AG 1x8 and extraction chromatographic sorbent TEVA resin. Developed “direct” generators resulted in the production of 226Th with high yield and purity as required for biomedical applications. Next, we prepared Nimotuzumab radioimmunoconjugates with thorium-234, a long-living analog of 226Th, using bifunctional chelating agents (BFCAs) p-SCN-Bn-DTPA and p-SCN-Bn-DOTA. Radiolabeling of Nimotuzumab with Th4+ was carried out by post-labeling method, using p-SCN-Bn-DTPA, and pre-labeling method, using p-SCN-Bn-DOTA.